This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Murphy, R. T. Articles by McKenna, W. J. Search for Related Content PubMed PubMed Citation Articles by Murphy, R. T. Articles by McKenna, W. J.

CLINICAL RESEARCH: HYPERTROPHIC CARDIOMYOPATHY

Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome

Natural history

The Heart Hospital, University College London, London, United Kingdom

Manuscript received June 14, 2004; revised manuscript received October 18, 2004, accepted November 22, 2004.

^* Reprint requests and correspondence: Dr. William J. McKenna, The Heart Hospital, 16-18 Westmoreland Street, London W1G 8PH, United Kingdom (Email: william.mckenna{at}uclh.org).

OBJECTIVES: The aim of this study was to investigate the clinical expression of adenosine monophosphate-activated protein kinase (AMPK) gene mutations (PRKAG2) in adenosine monophosphate (AMP) kinase disease based on 12 years follow-up of known mutation carriers and to define the prevalence of PRKAG2 mutations in hypertrophic cardiomyopathy (HCM).

BACKGROUND: Adenosine monophosphate-activated protein kinase gene mutations cause HCM with Wolff-Parkinson-White syndrome and conduction disease.

METHODS: Clinical evaluation of 44 patients with known AMP kinase disease was analyzed. Mutation analysis of PRKAG2 was performed by fluorescent single-strand confirmation polymorphism analysis and direct sequencing of abnormal conformers in 200 patients with HCM.

RESULTS: Only one additional mutation was identified. The mean age at clinical diagnosis in the 45 gene carriers was 24 years (median 20 years, range 9 to 55 years). Symptoms of palpitation, dypspnea, chest pain, or syncope were present in 31 (69%) gene carriers; 7 (15%) complained of myalgia and had clinical evidence of proximal myopathy. Skeletal muscle biopsy showed excess mitochondria and ragged red fibers with minimal glycogen accumulation. Disease penetrance defined by typical electrocardiogram abnormalities was 100% by age 18 years. Thirty-two of 41 adults (78%) had left ventricular hypertrophy (LVH) on echocardiography, and progressive LVH was documented during follow-up. Survival was 91% at a mean follow-up of 12.2 years. Progressive conduction disease required pacemaker implantation in 17 of 45 (38%) at a mean age of 38 years.

CONCLUSIONS: The AMP kinase disease is uncommon in HCM and is characterized by progressive conduction disease and cardiac hypertrophy and includes extracardiac manifestations such as a skeletal myopathy, consistent with a systemic metabolic storage disease. Defects in adenosine triphosphate utilization or in specific cellular substrates, rather than mere passive deposition of amylopectin, may account for these clinical features.

Abbreviations and Acronyms   AMP = adenosine monophosphate   AMPK = adenosine monophosphate-activated protein kinase   HCM = hypertrophic cardiomyopathy   LVH = left ventricular hypertrophy   MLVWT = maximum left ventricular wall thickness   NYHA = New York Heart Association   WPW = Wolff-Parkinson-White

This article has been cited by other articles:

				L. H. Young AMP-Activated Protein Kinase Conducts the Ischemic Stress Response Orchestra Circulation, February 12, 2008; 117(6): 832 - 840. [Full Text] [PDF]

				E. A. Stephenson and C. I. Berul Electrophysiological Interventions for Inherited Arrhythmia Syndromes Circulation, August 28, 2007; 116(9): 1062 - 1080. [Full Text] [PDF]

				P. Charron, M. Genest, P. Richard, M. Komajda, and G. Pochmalicki A familial form of conduction defect related to a mutation in the PRKAG2 gene Europace, August 1, 2007; 9(8): 597 - 600. [Abstract] [Full Text] [PDF]

				M. Arad, C. E. Seidman, and J.G. Seidman AMP-Activated Protein Kinase in the Heart: Role During Health and Disease Circ. Res., March 2, 2007; 100(4): 474 - 488. [Abstract] [Full Text] [PDF]

				S. D. Colan, S. E. Lipshultz, A. M. Lowe, L. A. Sleeper, J. Messere, G. F. Cox, P. R. Lurie, E. J. Orav, and J. A. Towbin Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry Circulation, February 13, 2007; 115(6): 773 - 781. [Abstract] [Full Text] [PDF]

				M. Jastrzebski, B. Bacior, P. P. Dimitrow, and K. Kawecka-Jaszcz Electrophysiological study in a patient with Fabry disease and a short PQ interval Europace, December 1, 2006; 8(12): 1045 - 1047. [Abstract] [Full Text] [PDF]

				J. K. Davies, D. J. Wells, K. Liu, H. R. Whitrow, T. D. Daniel, R. Grignani, C. A. Lygate, J. E. Schneider, G. Noel, H. Watkins, et al. Characterization of the role of {gamma}2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1942 - H1951. [Abstract] [Full Text] [PDF]